Concomitant stenting of the patent ductus arteriosus and radiofrequency valvotomy in pulmonary atresia with intact ventricular septum and intermediate right ventricle: Early in-hospital and medium-term outcomes

Mazeni Alwi, MRCP, Kok-Kuan Choo, MRCP, Nomee A. M. Radzi, MRCPCH, Hasri Samion, MD, Kiew-Kong Pau, FRCS, and Chee-Chin Hew, FRCS

Objectives: Our objective was to determine the feasibility and early to medium-term outcome of stenting the patent ductus arteriosus at the time of radiofrequency valvotomy in the subgroup of patients with pulmonary atresia with intact ventricular septum and intermediate right ventricle.

Background: Stenting of the patent ductus arteriosus and radiofrequency valvotomy have been proposed as the initial intervention for patients with intermediate right ventricle inasmuch as the sustainability for biventricular circulation or ½-ventricle repair is unclear in the early period.

Methods: Between January 2001 and April 2009, of 143 patients with pulmonary atresia and intact ventricular septum, 37 who had bipartite right ventricle underwent radiofrequency valvotomy and stenting of the patent ductus arteriosus as the initial procedure. The mean tricuspid valve z-score was $-3.8 \pm 2.2$ and the mean tricuspid valve/mitral valve ratio was $0.62 \pm 0.16$.

Results: Median age was 10 days (3–65 days) and median weight 3.1 kg (2.4–4.9 kg). There was no procedural mortality. Acute stent thrombosis developed in 1 patient and necessitated emergency systemic–pulmonary shunt. There were 2 early in-hospital deaths owing to low cardiac output syndrome. One late death occurred owing to right ventricular failure after the operation. Survival after the initial procedure was 94% at 6 months and 91% at 5 years. At a median follow-up of 4 years (6 months to 8 years), 17 (48%) attained biventricular circulation with or without other interventions and 9 (26%) achieved ½-ventricle repair. The freedom from reintervention was 80%, 68%, 58%, and 40% at 1, 2, 3, and 4 years, respectively.

Conclusions: Concomitant stenting of the patent ductus arteriosus at the time of radiofrequency valvotomy in patients with pulmonary atresia with intact ventricular septum and intermediate right ventricle is feasible and safe with encouraging medium-term outcome. (J Thorac Cardiovasc Surg 2011;141:1355-61)
catheter-based therapies. The tricuspid valve (TV) and mitral valve (MV) diameters were measured in diastole. The TV z-score was derived from the nomogram by Rowlett, Rimoldi, and Lev, and TV z-score was calculated. The RV cavity was also described as tripartite, depending on the number of parts of the RV (inlet, apical trabecular, and outlet) not obliterated by intracavity muscular overgrowth. Particular attention was paid to whether there was a well-formed infundibulum that ended in a membranous atresia or was obliterated by muscles (muscular atresia). TV regurgitation and its severity, if present, were noted as well as RV–coronary communications. Patients with a “good” RV are those with a TV z-score of more than –2.5, a TV/MV ratio of 0.75 or more, and membranous atresia with a well-formed infundibulum in which the RV cavity was described as tripartite. The RV volume was not measured quantitatively. Patients with a “severely diminutive” RV were defined as those having a TV z-score of less than –5.0, a TV/MV ratio of less than 0.5, and an RV cavity described as unipartite, in which only the inlet component was present and the infundibulum was absent or slitlike. These 2 subgroups were excluded from the study. Also excluded were patients with branch pulmonary artery stenosis, usually the left at the site of ductal insertion. The subjects of this study, termed as having “intermediate” RV morphology, were those with a TV z-score of –2.5 to –5.0 and/or a TV/MV ratio of 0.50 to 0.75, with the RV described as “bipartite,” where apart from the inlet component, a well-formed infundibulum ends in a membranous atresia but the apical trabecular component is absent or attenuated. The decision for recruitment into the study was made by a consensus of 2 of the authors (M.A. and H.S.). Ethics committee approval was obtained.

**RFV and PDA Stenting, Postprocedure Care**

All patients were subjected to cardiac catheterization under general anesthesia with a view toward catheter-based intervention. Patients with a good RV underwent RFV only. Patients with a severely diminutive (unipartite) RV received PDA stenting only if the PDA was suitable; otherwise, they were referred for systemic–pulmonary shunt. The study patients, those with an intermediate RV, received RFV and concomitant PDA stenting. Prostaglandin E$_2$ was discontinued the evening before the procedure to ensure the PDA was restrictive. Informed consent was obtained. Baseline hemodynamic data and oxygen saturation were obtained. RV angiogram was performed to delineate the RV cavity, particularly the infundibulum, the valve, and subvalvular area, and to document RV–coronary communications and the possibility of RV-dependent coronary circulation. RV decompression with RFV was not performed in the presence of RV-dependent coronary circulation. Aortic arch angiography was performed to delineate the PDA and the pulmonary artery anatomy for the purpose of PDA stenting. RFV and PDA stenting were performed using techniques and equipment as previously described. Coronary stents were used and the sizes chosen were 3.5 mm for patients weighing 2.5 to 2.9 kg, 4.0 mm for those weighing 3.0 to 3.5 kg, and 4.5 mm for those weighing more than 3.5 kg. The stent length was according to that of the PDA. All procedures were done by the transfemoral route. PDA stenting was not performed if branch pulmonary artery stenosis at the site of ductal insertion was shown by angiography. Early in the series, balloon atrial septostomy was also performed if the patent foramen ovale was restrictive, but this was subsequently omitted because we believed that a large interatrial communication would reduce flow to the TV and impair RV growth. After the procedure, the patients were returned to the intensive care unit for continued ventilation and inotropic support as necessary. Heparin infusion was given for 2 days and oral aspirin started the following day and continued until the end point was reached.

**Immediate Early Outcome, Follow-up, and Subsequent Procedures**

Patients were discharged from the intensive care unit if they could be extubated, could maintain an oxygen saturation greater than 75% in air, and could maintain stable hemodynamics without inotropic support. Early reintervention is defined as the patient requiring a systemic–pulmonary shunt within 30 days of the procedure owing to oxygen saturation less than 70% or requiring other surgical/catheter procedures. After discharge, the patients were reviewed at 1 month, 3 months, and then every 6 months. The degree of cyanosis was assessed clinically. The major tool for evaluation was echocardiography, focusing on the growth of the RV by measuring the TV and MV, and a general assessment of RV cavity, in particular the apical trabecular component. Tricuspid regurgitation, if present, was monitored as well as any residual or recurrence of valvular or subvalvular stenosis. The flow through the ductal stent was noted. The end points were death before subsequent procedures and, for the surviving patients, attainment of either 2-ventricle circulation or 1½-ventricle circulation. The patients were described as having 2-ventricle circulation and no further treatment was deemed necessary if there was no obvious clinical cyanosis, the echocardiographic evaluation fit the description of tripartite RV with a gradient of 40 mm Hg or less across the RV outflow tract (RVOT), absent or minimal flow through the PDA, and minimal shunt through the patent foramen ovale. Significant additional problems, if present, such as RVOT obstruction owing to subvalvular muscular overgrowth or hypoplastic pulmonary annulus, shunts through the ASD or PDA, and tricuspid regurgitation were addressed before being categorized as having attained the 2-ventricle circulation.

Patients who remained cyanotic despite good antegrade flow and whose RV growth remained inadequate after 36 to 60 months were subjected to 1½-ventricle circulation by having bidirectional cavopulmonary shunt. Prior cardiac catheterization was performed partly to specifically look for branch left pulmonary artery stenosis as a possible late complication of PDA stenting. At the time of the bidirectional cavopulmonary procedure, the ASD was closed, the PDA stent divided, and additional problems, if present, such as TV regurgitation, RVOT obstruction, pulmonary annular hypoplasia, and branch left pulmonary artery stenosis were addressed accordingly. Patients who had not reached either end point were considered as “awaiting.”

**Analysis of Data**

The SPSS statistical program for Windows, version 17.0 (SPSS, Inc., Chicago, Ill), was used for data analysis. Data was expressed as mean ± SD, median (range), and frequency (percentage). Survival and freedom from reinterventions were determined by the Kaplan–Meier method. Reintervention was defined as either catheter-based intervention or surgery.

**RESULTS**

Between January 2001 and April 2009, 143 patients with PAIVS were referred to our institution. Forty-five patients had good RV (tripartite) and underwent RFV only.
Sixty-one patients had severely diminutive RV (unipartite) and received PDA stenting only. Thirty-seven patients, who formed the subjects of this study (ie, intermediate RV size [bipartite]), received RFV and elective PDA stenting as the initial procedure. Early in the series, 8 (22%) patients received additional balloon atrial septostomy. The median age at procedure was 10 days (3–65 days) and the mean weight was 3.1 kg (2.6–4.9 kg). The TV z-score was $-3.8 \pm 2.2$. The TV/MV ratio was $0.62 \pm 0.16$ (Table 1).

In all patients the RV cavity was described as bipartite, having definite inlet and infundibular components with membranous atresia, whereas the apical trabecular component was severely attenuated. Moderate-to-severe tricuspid regurgitation was present in 12 (32%) patients. Major sinuoids were present in 3 (8.1%) patients, but none had RV-dependent coronary circulation.

The mean procedural time was $111 \pm 39$ minutes. The median duration of ventilatory support was 1 day (1–15 days). The median length of hospital stay was 8 days (4–23 days) (Table 1).

Mortality and Complications
There was no procedural mortality. Two (5%) patients had transient supraventricular tachycardia. One patient had acute stent thrombosis within 24 hours, necessitating systemic–pulmonary shunt. Loss of femoral arterial pulse occurred in 5 (14%) patients and was successfully treated with heparin and streptokinase.

There were 2 early in-hospital deaths owing to low cardiac output at 10 and 12 days after the procedure. One of these patients had major sinuoids and the other had pulmonary overcirculation. One late death was due to RV failure after RVOT reconstruction surgery. Survival after the initial procedure was 94% at 6 months and remained at 91% from 1 to 4 years (Figure 1).

Follow-up
At a median follow-up of 4 years (6 months to 8.2 years), 8 (23%) patients had not reached the study end point (follow-up <24 months; ie, “awaiting”). Seventeen (48%) attained biventricular circulation, 8 of whom required reinterventions: transcatheter closure of ASD ($n = 2$), repeat balloon pulmonary valvuloplasty ($n = 1$), surgical RVOT reconstruction ($n = 4$), and PDA restenting and balloon pulmonary valvuloplasty at 3 months, followed by RVOT reconstruction at 14 months ($n = 1$). Nine (26%) patients did not achieve sufficient RV growth and received bidirectional cavopulmonary shunt, ASD closure, and PDA stent division (1½-ventricle repair), of whom 3 (33%) also received RVOT reconstruction (Figure 1). No patient had left pulmonary artery stenosis.

The freedom from reintervention was 80%, 68%, 58%, and 40% at 1, 2, 3, and 4 years, respectively (Figure 2).

---

**TABLE 1. Demographic, echocardiographic, periprocedural, and follow-up data**

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age (d)</td>
<td>10 (3–65)</td>
</tr>
<tr>
<td>Median weight (kg)</td>
<td>3.1 (2.6–4.9)</td>
</tr>
<tr>
<td>Mean TV/MV ratio</td>
<td>$0.62 \pm 0.16$</td>
</tr>
<tr>
<td>Mean z-score of TV annulus</td>
<td>$-3.8 \pm 2.2$</td>
</tr>
<tr>
<td>Median procedure time (min)</td>
<td>111 ± 39</td>
</tr>
<tr>
<td>Median ventilation days (d)</td>
<td>1 (1–15)</td>
</tr>
<tr>
<td>Median length of hospital stay (d)</td>
<td>8 (4–23)</td>
</tr>
<tr>
<td>Median follow up (y)</td>
<td>4 (½–8.2)</td>
</tr>
</tbody>
</table>
However, for those who attained biventricular circulation, the freedom from reintervention was 77%, 70%, 70%, and 61% at 1, 2, 3, and 4 years, respectively (Figure 3).

The mean TV score at presentation for those who attained biventricular circulation and 1½-ventricle repair was $-2.8 \pm 1.8$ and $-4.1 \pm 2.3$, respectively.

**DISCUSSION**

The wide variation of RV morphology in PAIVS has long been recognized and management algorithms have largely been based on this.1-3 At one end of the morphologic spectrum are those with a good RV in whom the 3 components of the RV cavity are reasonably well developed—the inlet, apical trabecular, and outlet or infundibulum—even if the RV in general is smaller than that of the normal population. The atresia in this group of patients is membranous in nature. This is the group with the most favorable outcome, comprising 50% to 60% of patients. RV decompression and establishing unobstructed antegrade flow into the pulmonary circulation by surgical valvotomy or RFV in the neonatal period is often the only procedure required, the latter being the favored method of treatment today.4

At the other end are those with severely diminutive RV with obliteration of the apical trabecular and infundibular cavity. These patients are inevitably destined for the Fontan track.5,12 Inasmuch as they are ductus dependent, an initial palliation with systemic–pulmonary shunt is required. PDA stenting, being less invasive, is an attractive alternative to surgical shunt. This is particularly suited to PAIVS, in which the ductus tends to be more amenable to stenting compared with other forms of cyanotic heart disease.11,13,14 This is our preferred mode of initial management.

However, a significant proportion of patients do not exhibit RV features that clearly suggest either the favorable 2-ventricle eventual outcome or the less favorable single-ventricle pathway. In our algorithm, this subgroup of patients was designated “intermediate.”6 The characteristic features on echocardiography that define this subgroup are TV z-score $-2.5$ to $-5.0$, MV/TV ratio 0.5 to 0.75, and an RV cavity that has a severely attenuated apical trabecular component but with a reasonably well-developed infundibulum that ends with a membranous valvular atresia, “bipartite RV.”

Somewhat out of this continuum of RV morphology are the rare patients with Ebstein anomaly, who have a markedly dilated, thin-walled, poorly functioning RV with severe tricuspid regurgitation.2 Even today the outlook is very poor, with or without intervention.

Catheter-based therapies have markedly altered the management of PAIVS. RFV is currently the preferred method of initial management, achieving results comparable with if not superior to conventional surgery.4,7,8 The PDA in this condition tends to arise obtusely from the descending aorta to insert onto the dome of the main pulmonary artery rather than onto the proximal left pulmonary artery, making PDA stenting an attractive alternative to systemic–pulmonary shunt. Transcatheter device closure of shunts at ASD or PDA levels can be done as the final procedure. Radical surgery, such as RVOT reconstruction in the neonatal period, is associated with high mortality and morbidity.12 However, surgery remains an important part of management of PAIVS, especially for those with severely diminutive RV who require the Fontan operation.5,12,15,16 In patients with intermediate RV that remains incapable of independently supporting the pulmonary circulation, the bidirectional cavopulmonary shunt is an integral part of the 1½-ventricle repair.17,19 Although data are currently lacking, we are of the opinion that in the long term the 1½-ventricle circulation is
preferable to the Fontan circulation inasmuch as some of the major late complications of the Fontan operation are attributed to the absence of pulsatile flow. This is our basis for this management strategy for those with borderline, “intermediate” RV. Surgery may also be additionally required in patients with fixed RVOT obstruction and severe tricuspid regurgitation in both the 2-ventricle and 1½-ventricle pathways.

Less Ideal RV Size and the Basis for “Prophylactic” PDA Stenting

The focus of our interest is on the subgroup of patients with borderline or “intermediate” RV, one that is difficult to determine at the time of presentation whether it would eventually be capable of sustaining the pulmonary circulation (2-ventricle) or have to be supported by a bidirectional cavopulmonary shunt (1½-ventricle). The initial management of patients with intermediate RV as defined herein is somewhat less clear-cut than those with good tripartite RV or those with severely diminutive RV.

In the surgical era, closed valvotomy or transannular patch with concomitant systemic–pulmonary shunt is a popular management strategy for all patients with patent infundibulum.20,21 It was not uncommon for patients to require such a shunt within days of surgical valvotomy alone owing to unacceptably low arterial oxygen tension, hence the concept of “prophylactic” systemic–pulmonary shunt at the time of valvotomy. A parallel situation was encountered in the era of transcatheter management with RFV. In a relatively large series of PAIVS patients with seemingly good RV (mean TV z-score –1.33), 14 of 27 patients who successfully underwent RFV required the construction of a systemic–pulmonary shunt (1½-ventricle). The initial management of patients with intermediate RV as defined herein is somewhat less clear-cut than those with good tripartite RV or those with severely diminutive RV.

From our experience, PDA stenting is a reasonable alternative to the Blalock–Taussig shunt in a selected group of patients. However, one needs to be mindful of the possible complications, such as acute stent thrombosis, aggressive neointimal proliferation causing early stent flow restriction, and late branch pulmonary artery stenosis in those in whom the ductus is inserted at the left pulmonary artery. Hence, this has to be excluded at the initial evaluation.11 In PAIVS, RFV and PDA stenting may cause overcirculation and myocardial ischemia, in particular in those with coronary sinusoids.

In this series, major late complications of PDA stenting were not encountered and a stented PDA did not pose a major surgical challenge at the time of bidirectional cavopulmonary shunt, where the stent was crushed, sutured with 5–0 Prolene polypropylene (Ethicon, Inc, Somerville, NJ), and divided.

As anticipated, not all patients attained 2-ventricle circulation, where normal oxygen saturation is achieved with the RV supporting the entire pulmonary circulation and all shunts abolished. It was also not surprising that 50% of patients who did attain the 2-ventricle end point required reinterventions in the form of RVOT reconstruction, ASD closure, and TV repair given that they started off with less ideal morphology. Twenty-six percent of patients did not achieve sufficient RV “growth” after 3.7 years ± 2.9 years and received bidirectional cavopulmonary shunt, ASD closure, and PDA stent division (1½-ventricle repair).

RV “Growth”

The potential for growth of the RV after decompression and establishment of forward flow is difficult to predict. There have been many published series documenting anatomic growth of the RV, in part contributed by pulmonary
regurgitation after valvotomy and regression of muscular hypertrophy after RV decompression. This is also illustrated by 1 of our patients (Figure 4, A–E). On the other hand, there seem at times, overly optimistic expectations on the capacity for the RV to grow inasmuch as there are also data that showed no significant catch-up anatomic growth of the TV. However, even if there is no catch-up growth, some patients were still able to attain 2-ventricle circulation despite the subnormal RV size. It is thus difficult to determine the size of the RV that will contribute to a successful 2-ventricle circulation. It appears that normal TV growth is not mandatory to have an RV capable of sustaining the pulmonary circulation. “Physiologic” growth, that is, improved compliance, is of greater import.

FIGURE 4. A, Right ventricular (RV) handshot showing bipartite RV with fairly well-developed infundibulum with membranous atresia (thick arrow) and inlet component (thin arrow). Muscle-bound apical trabecular component of RV is the area within dotted lines. Except for the intertrabecular recesses, the cavity is virtually obliterated. Membranous atresia seen. RV/aortic pressures = 153:73 mm Hg. B, RV angiogram after radiofrequency valvotomy and balloon dilatation. Transient reactive spasm reduces RV outflow tract cavity. C, Patent ductus arteriosus crossed with a balloon-mounted coronary stent retrogradely. D, Stent expanded and covering the full length of the patent ductus arteriosus. E, RV angiogram 4 years after radiofrequency-assisted valvotomy and PDA stenting showing a well developed RV, unobstructed pulmonary blood flow, no branch pulmonary artery stenosis, and regression of muscular overgrowth resulting in a well-formed cavity of apical component of RV. Excellent overall growth of RV; “tripartite” end state. The patent ductus arteriosus stent is hardly visible.
than anatomic growth. In the face of these uncertainties, RV decompression provides the opportunity for the RV to attain its maximal potential for “growth,” both anatomic and physiologic. This can be done less invasively by RFV, and PDA stenting helps support the pulmonary circulation in the interim until either of the end points is reached.

CONCLUSIONS

Concomitant PDA stenting at the time of RFV in PAIVS patients with intermediate RV size is feasible and safe. This treatment strategy largely obviated the need for emergency procedures to augment pulmonary blood flow although acute stent thrombosis may occur in a small percentage.

A quarter of patients with intermediate RV eventually required bidirectional cavopulmonary shunt (1½-ventricle), whereas among those who attained biventricular circulation, a significant proportion required additional procedures. Concomitant with RFV, PDA stenting should be considered an integral part of the initial management in PAIVS with intermediate RV. However, inasmuch as PDA stenting is a relatively new procedure and PAIVS is an uncommon disease, this management strategy warrants wider, multi-institutional study.

We greatly appreciate the help of Muhaneeza Hanafiah in the preparation of the manuscript and Mohd Faizal Ramli for his assistance in the statistical analysis.

References